Eupraxia pharmaceuticals announces voting results from annual general and special meeting of shareholders

Victoria, british columbia, june 02, 2025 (globe newswire) -- eupraxia pharmaceuticals inc. (“eupraxia” or the “company”) (tsx: eprx) (nasdaq: eprx), a clinical-stage biotechnology company leveraging its proprietary diffusphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its annual general and special meeting of shareholders (the “meeting”) held on june 2, 2025. pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the company's board of directors (the “board”) at the meeting and listed in the company's management information circular dated april 25, 2025, were elected.
GM Ratings Summary
GM Quant Ranking